Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells

Carcinogenesis

Volumn 27, Issue 6, 2006, Pages 1134-1145

  Mi, Zhiyong ^a   Guo, Hongtao ^a   Wai, Philip Y ^a   Gao, Chengjiang ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CELL SURFACE PROTEIN; GELATINASE A; INTEGRIN; INTEGRIN LINKED KINASE; INTEGRIN RECEPTOR; OSTEOPONTIN; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR AP 1; UROKINASE; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL ADHESION; CELL FUNCTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; EXPERIMENTAL STUDY; GENE CONSTRUCT; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; IN VITRO STUDY; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPORTER GENE; UPREGULATION;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MATRIX METALLOPROTEINASE 2; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOPONTIN; PROTEIN-SERINE-THREONINE KINASES; SIALOGLYCOPROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 33745605192     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi352     Document Type: Article

References (49)

1. Denhardt,D.T., Lopez,C.A., Rollo,E.E., Hwang,S.M., An,X.R. and Walther,S.E. (1995) Osteoponfin-induced modifications of cellular functions. Ann. NY Acad. Sci., 760, 127-142.
2. Denhardt,D.T., Giachelli,C.M. and Rittling,S.R. (2001) Role of osteopontin in cellular signaling and toxicant injury. Annu, Rev. Pharmacol. Toxicol, 41, 723-749.
3. Weber,G.F., Ashkar,S. and Cantor,H. (1997) Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc. Assoc. Am Physicians.,109, 1-9.
4. Denhardt,D.T. and Chambers,A.F, (1994) Overcoming obstacles to metastasis-defenses against host defences: Osteopontin as a shield against attack by cytotoxic host cells. J. Cell Biochem., 56, 48-51.
5. Brown,L.F., Papadopoulos-Sergiou,A., Berse,B., Manseau,E.J., Tognazzi, K., Perruzzi,C.A., Dvorak,H.F. and Senger,D.R. (1994) Osteopontin expression and distribution in human carcinomas. Am. J. Pathol., 145, 610-623.
6. Agrawal,D., Chen,T., Irby,R., Quackenbush,J., Chambers,A.F., Szabo,M., Cantor,A., Coppola,D. and Yeatman,T.J. (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J. Natl Cancer Inst., 94, 513-521.
7. Coppola,D., Szabo,M., Boulware,D., Muraca,P., Alsarraj,M., Chambers,A.F. and Yeatman,T.J. (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin. Cancer Res., 10, 184-190.
8. Das,R., Mahabeleshwar,G.H. and Kundu,G.C. (2003) Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem., 278, 28593-28606.
9. Fedarko,N.S., Jain,A., Karadag,A., Van Eman,M.R. and Fisher,L.W. (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin. Cancer Res., 7, 4060-4066.
10. Gotoh,M., Sakamoto,M., Kanetaka,K., Chuuma,M. and Hirohashi,S. (2002) Over expression of osteopontin in hepatocellular carcinoma. Pathol. Int., 52, 19-24.
11. Grano,M., Mori,G., Minielli,V., Colucci,S., Vaira,S., Giannelli,G., Martemucci,S., Giorgino,F. and Zallone,A.Z. (2002) HGF and M-CSF modulate adhesion of MDA-231 breast cancer cell by increasing osteopontin secretion. J. Biol. Regul. Homeost. Agents, 16, 190-195.
12. Pantel,K. and Brakenhoff,R.H. (2004) Dissecting the metastatic cascade. Nat. Rev. Cancer, 4, 448-456.
13. Ahmad,S.A., Berman,R.S. and Ellis,L.M. (2003) Biology of colorectal liver metastases. Surg. Oncol. Clin. N. Am., 12, 135-150.
14. Berman,R.S., Portera,C.A.,Jr and Ellis,L.M. (2001) Biology of liver metastases. Cancer Treat. Res., 109, 183-206.
15. Mi,Z., Guo,H., Wai,P.Y., Gao,C., Wei,J. and Kuo,P.C. (2004) Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J. Biol Chem., 279, 46659-46667.
16. HeppnerG.H., Miller,F.R. and Shekhar,P.M. (2000) Nontransgenic models of breast cancer. Breast Cancer Res., 2, 331-334.
17. Hannigan,G.E., Leung-Hagesteijn,C., Fitz-Gibbon,L., Coppolino,M.G., Radeva,G., Filmus,J., Bell,J.C. and DedbarS. (1996) Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature, 379, 91-96.
18. Gao,C., Guo,H., Wei,J., Mi,Z., Wai,P. and Kuo,P.C. (2004) S-nitrosylation of hnRNP-A/B regulates osteopontin transcription in endotoxin-stimulated murine macrophages. J. Biol. Chem., 279, 11236-11243.
19. Hannigan,G., Troussard,A.A. and Dedhar,S. (2005) Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat. Rev. Cancer, 5, 51-63.
20. Denhardt,D.T., Noda,M., O' Regan,A.W., Pavlin,D. and Berman,J.S. (2001) Osteopontin as a means to cope with environmental insults: Regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest., 107, 1055-1061.
21. Attur,M.G., Dave,M.N., Stuchin,S., Kowalski,A.J., Steiner,G., Abramson,S.B., Denhardt,D.T. and Amin,A.R. (2001) Osteopontin: An intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum., 44, 578-584.
22. Craig,A.M. and Denhardt,D.T. (1991) The murine gene encoding secreted phosphoprotein 1 (osteopontin): Promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene, 100, 163-171.
23. Denhardt,D.T. and Guo,X.J. (1993) Osteopontin: A protein with diverse functions. FASEB J., 7, 1475-1482.
24. O'Regan,A. and Berman,J.S. (2000) Osteopontin: A key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol., 81, 373-390.
25. WeberG.F. (2001) The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim. Biophys. Acta, 1552, 61-85.
26. Senger,D.R., Asch,B.B., Smith,B.D., Perruzzi,C.A. and Dvorak,H.F. (1983) A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature, 302, 714-715.
27. Senger,D.R., Penuzzi,C.A., Gracey,C.F., Papadopoulos,A. and Tenen,D.G. (1988) Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res., 48, 5770-5774.
28. Bautista,D.S., Xuan,J.W., Hota,C., Chambers,A.F. and Harris,J.F. (1994) Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. Biol, Chem., 269, 23280-23285.
29. Hijiya,N., Setoguchi,M., Matsuura,K., Higuchi,Y., Akizuki,S. and Yamamoto,S. (1994) Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J., 303, 255-262.
30. Carlinfante,G., Vassilioul,D., Svensson,O., Wendel,M., Heinegard,D. and Andersson,G. (2003) Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin. Exp. Metastasis, 20, 437-444.
31. Korkola,J.E., DeVries,S., Fridlyand,J., Hwang,E.S., Estep,A.L., Chen,Y.Y., Chew,K.L., Dairkee,S.H., Jensen,R.M. and Waldman,F.M. (2003) Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res.,63, 7167-7175.
32. Rangaswami,H., Bulbule,A. and Kundu,G.C. (2005) JNK1 differentially regulates osteopontin-induced nuclear factor-inducing kinase/ MEKK1-dependent activating protein-1-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem., 280, 19381-19392.
33. Rangaswami,H., Bulbule,A. and Kundu,G.C. (2004) Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem., 279, 38921-38935.
34. Das,R., Mahabeleshwar,G.H. and Kundu,G.C. (2004) Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J. Biol. Chem, 279, 11051-11064.
35. Philip,S., Bulbule,A. and Kundu,G.C. (2001) Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metallo-proteinase in murine melanoma cells. J. Biol. Chem., 276, 44926-44935.
36. Philip,S. and Kundu,G.C. (2003) Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J. Biol. Chem., 278, 4487-14497.
37. Tuck,A.B., Hota,C. and Chambers,A.F. (2001) Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res. Treat., 70, 197-204.
38. Tuck,A.B. and Chambers,A.F. (2001) The role of osteopontin in breast cancer: Clinical and experimental studies. J. Mammary Gland Biol. Neoplasia., 6, 419-429.
39. Tan,C., Cruet-Hennequart,S., Troussard,A., Fazli,L., Costello,P., Sutton,K., Wheeler,J., Gleave,M., Sanghera,J. and Dedhar,S. (2004) Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell, 5, 79-90.
40. Edwards,L.A., Thiessen,B., Dragowska,W.H., Daynard,T., Bally,M.B. and Dedhar,S. (2005) Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth. Oncogene, 24, 3596-3605.
41. Marotta,A., Parhar,K., Owen,D., Dedhar,S. and Salh,B. (2003) Characterisation of integrin-linked kinase signaling in sporadic human colon cancer. Br. J. Cancer, 88, 1755-1762.
42. Persad,S., Attwell,S., Gray,V., Delcommenne,M., Troussard,A., Sanghera,J. and Dedhar,S. (2000) Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc. Natl Acad Sci. USA, 97, 3207-3212.
43. Somasiri,A., Howarth,A., Goswami,D., Dedbar,S. and Roskelley,C.D. (2001) Over expression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells. J. Cell Sci., 114, 1125-1136.
44. Tan,C., Costello,P., Sanghera,J., Dominguez,D., Baulida,J., de Herreros,A.G. and Dedhar,S. (2001) Inhibition of integrin linked kinase (ILK) suppresses beta-catenin-Lef/Tcf-dependent transcription and expression of the E-cadherin repressor, snail, in APC-/- human colon carcinoma cells. Oncogene, 20, 133-140.
45. White,D.E., Cardiff,R.D., Dedhar,S. and Mulle,W.J. (2001) Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene, 20, 7064-7072.
46. Attwell,S., Roskelley,C. and Dedhar,S. (2000) The integrin-linked kinase (ILK) suppresses anoikis. Oncogene, 19, 3811-3815.
47. Filipenko,N.R., Attwell,S., Roskelley,C. and Dedhar,S. (2005) Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene, 24, 5837-5849.
48. Novak,A., Hsu,S.C., Leung-Hagesteijn,C., Radeva,G., Papkoff,J., Montesano,R., Roskelley,C., Grosschedl,R. and Dedhar,S. (1998) Cell adhesion and the integrin-linked kinase regulate the LEF-1 and beta-catenin signaling pathways. Proc. Natl Acad. Sci. USA, 95, 4374-4379.
49. Troussard,A.A., Costello,P., Yoganadian,T.N., Kumagai,S., Roskelley,C.D. and Dedhar,S. (2000) The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene, 19, 5444-5452.